Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Peripheral Spondyloarthritis (ABILITY-2)
NCT01064856Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2010
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in peripheral spondyloarthritis (pSpA) comparing Double-blind Adalimumab with Double-blind Placebo (2 arms). Primary endpoints: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at 12 weeks and Number of Participants With Adverse Events at 156 weeks. Started Feb 2010; status: completed.
02
Drugs
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NCT01064856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064856.